anayamalik, Author at European Medical Journal - Page 44 of 83

How Wildfires Lengthened Hospital Stays Post Lung Cancer Surgery

Patients recovering from lung cancer surgery may face prolonged hospital stays when wildfires strike, according to new research examining the effects of wildfire disasters on post-operative recovery.

Brain Stimulation and Exercise Cut Smoking Cravings

A new randomized controlled trial has found that combining transcranial direct current stimulation (tDCS) with aerobic exercise (AE) significantly reduces cigarette cravings and consumption in chronic smokers.

New Biosensor Detects H5N1 and E. coli in Minutes

A capacitive biosensor has been developed that offers real-time airborne detection of avian influenza H5N1 and E. coli, providing a rapid, sensitive tool for disease surveillance.

How Reliable Is the New Scleroderma Skin Questionnaire?

The psychometric properties of the Scleroderma Skin Questionnaire (SSQ), a novel patient-reported outcome (PRO) designed to assess skin disease in patients with systemic sclerosis (SSc), has been evaluated in a new study.

Children Drive RSV Spread Within U.S. Households

Respiratory syncytial virus (RSV) transmission in U.S. households was examined in a new study that showed young children are the primary drivers of infection, spreading the virus to adults and other household members.

Hidden Cognitive Decline in MS: A New Concern

Cognitive decline in relapsing-remitting multiple sclerosis (RRMS) can progress independently of both relapses and MRI-detected disease activity, challenging traditional methods of monitoring MS progression, according to the results of a new study.

Deep Learning Enhances NSCLC Treatment Precision

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

Twice-Yearly Biologic Shows Long-Term Safety in Asthma

A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy profile in patients with type 2 asthma.

COVID-19 Booster Protection: How Long Does It Last?

Analysis of over 1.5 million U.S. adults in a new study has found that annual COVID-19 variant-targeted boosters provide meaningful protection against severe disease but lose effectiveness beyond 6 months.

Cancer Outcomes in Rheumatoid Arthritis: Increased Mortality Rates

A recent long-term population study from Western Australia has revealed critical insights into the relationship between rheumatoid arthritis (RA) and cancer outcomes.